Home > > > > Report Detail

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2018

Publisher Name :
Date: 16-Oct-2018
No. of pages: 91
Inquire Before Buying

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acid Sphingomyelinase Deficiency Type C - Pipeline Review, H2 2018, provides an overview of the Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline landscape.

Niemann-Pick C disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. It involves the accumulation of sphingolipids in cells throughout the body, particularly reticuloendothelial cells (the mononuclear phagocyte system). Symptoms include enlarged liver, brain damage, difficulty walking and swallowing, increased sensitivity to touch, difficulty speaking, loss of muscle tone, learning difficulties.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acid Sphingomyelinase Deficiency Type C - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 8 and 4 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency Type C (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Overview
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Companies Involved in Therapeutics Development
Amicus Therapeutics Inc
CTD Holdings Inc
MallInckrodt Plc
Merck & Co Inc
Okklo Life Sciences BV
Orphazyme A/S
Perlara PBC
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Drug Profiles
acetylleucine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adrabetadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arimoclomol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Delta-tocopherol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Acid Sphingomyelinase Deficiency Type C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NPC1 for Niemann-Pick Type C1 Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAUR-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MLSA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit oxLDL for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKL-1014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PERL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RND-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Atherosclerosis and Niemann-Pick Type C Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Niemann-Pick Type C Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Cholesterol for Niemann-Pick Type C Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Cholesterol for Niemann-Pick Type C Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trappsol Cyclo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Dormant Projects
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Product Development Milestones
Featured News & Press Releases
Oct 05, 2018: CTD Holdings establishes second clinical trial site for us phase I clinical study of Trappsol Cyclo for treatment of Niemann-Pick Disease Type C
Oct 03, 2018: CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol Cyclo administered intravenously in Niemann Pick Disease Type C (NPC)
Sep 28, 2018: Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
Sep 13, 2018: CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals
Aug 30, 2018: CTD Holdings discusses its Phase I clinical trial for intravenous use of Trappsol Cyclo in Niemann-Pick Disease Type C
Aug 23, 2018: CTD Holdings' Trappsol Cyclo featured in television program on Niemann-Pick Disease Type C
Aug 13, 2018: CTD Holdings announces expanded access protocol using Intravenous Trappsol Cyclo for Alzheimer's disease
Jun 27, 2018: CTD to Present at National Niemann-Pick Disease Foundation Annual Conference
Jun 04, 2018: Orphazyme Presents at 2018 Parseghian Scientific Conference for Niemann-Pick Type C Research
Apr 30, 2018: FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol Cyclo Trial for Niemann-Pick Disease Type C
Mar 29, 2018: CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol Cyclo to Treat Niemann-Pick Disease Type C
Jan 19, 2018: Arimoclomol For NPC Receives Rare Pediatric Disease Designation
Dec 06, 2017: CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol Cyclo
Sep 28, 2017: CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol Cyclo for Treatment of Niemann-Pick Disease Type C
Sep 18, 2017: CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol Cyclo in Patients with Niemann-Pick Type C Disease in Israel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by Amicus Therapeutics Inc, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by CTD Holdings Inc, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by MallInckrodt Plc, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by Merck & Co Inc, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by Okklo Life Sciences BV, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by Orphazyme A/S, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline by Perlara PBC, H2 2018
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Genome Editing Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 111
    Market Overview of Global Genome Editing market: According to our latest research, the global Genome Editing market looks promising in the next 5 years. As of 2022, the global Genome Editing market was estimated at USD 7377.87 million, and it's anticipated to reach USD 25474.29 million in 2028, with a CAGR of 22.94% during the forecast years. Genome editing is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organ......
  • Global Genome Editing Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 86
    Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in target......
  • Animal Genetics Market by Product (Live Animal (Poultry, Porcine, Bovine, Canine) Genetic Material (Semen (Bovine, Porcine, Equine), Embryo (Bovine, Equine)) Genetic Testing Service (Disease, Genetic Traits - Bovine, DNA Typing)) - Global Forecast to 2028
    Published: 10-Aug-2023        Price: US 4950 Onwards        Pages: 320
    Rising demand for livestock animals due to the growing population, increasing per capita income, and rapid urbanization will drive the market growth. The global animal genetics market is projected to reach USD 9.5 billion by 2028 from USD 6.6 billion in 2023, at a CAGR of 7.4% during the forecast period. The increasing consumption of animal products, adoption of advanced genetic testing methods, animal welfare activities, and demand for companion animals are fueling the growth of this......
  • Epigenetic Therapeutics: Global Markets
    Published: 01-Jun-2023        Price: US 5500 Onwards        Pages: 155
    Report Scope: This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW). ......
  • Genome Editing Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030
    Published: 05-May-2023        Price: US 4150 Onwards        Pages: 146
    The study predicts the short term and long term trends that can shape up the future of the Genome Editing market including the COVID-19 pandemic implications for Genome Editings industry. The report presents market size forecasts across types, applications, end users and countries across regions. Strategic imperatives for development managers, decision makers and industry professionals including market trends, drivers, challenges, five forces analysis, insights on markets and companies. ......
  • Global Genome Editing Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 16-Mar-2023        Price: US 3260 Onwards        Pages: 95
    Genome editing is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations. The Genome Editing market revenue was 7377.87 Million USD in 2022, and will reach 25474.29 Million USD in 2028, with a CAGR of 22.94% during 2022-2028. This report elabo......
  • Global Genome Editing/Genome Engineering Market Status and Outlook 2023-2028
    Published: 01-Mar-2023        Price: US 3160 Onwards        Pages: 108
    Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging ......
  • Global Genome Engineering Market Status and Outlook 2023-2028
    Published: 23-Feb-2023        Price: US 3160 Onwards        Pages: 107
    Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in......
  • Global Genome Editing Market Research Report 2023
    Published: 07-Feb-2023        Price: US 2900 Onwards        Pages: 85
    Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in target......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs